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Here we determined if vitamin D deficiency is more common
in children with chronic kidney disease compared to healthy
children. In addition, we sought to identify disease-specific
risk factors for this deficiency, as well as its metabolic
consequences. We found that nearly half of 182 patients
(ages 5 to 21) with kidney disease (stages 2 to 5) and
a third of age-matched 276 healthy children were
25-hydroxyvitamin D deficient (o20ng/ml). The risk of
deficiency was significantly greater in advanced disease.
Focal segmental glomerulosclerosis and low albumin were
significantly associated with lower 25-hydroxyvitamin D,
which, in turn, was associated with significantly higher
intact parathyroid hormone levels. We found that
25-hydroxyvitamin D levels were positively associated with
1,25-dihydroxyvitamin D, the relationship being greatest
in advanced disease (significant interaction), and inversely
related to those of inflammatory markers C-reactive
protein and IL-6. The association with C-reactive protein
persisted when adjusted for the severity of kidney
disease. Thus, lower 25-hydroxyvitamin D may contribute
to hyperparathyroidism, inflammation, and lower
1,25-dihydroxyvitamin D in children and adolescents,
especially those with advanced kidney disease.
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Vitamin D deficiency is common in children and adults, and
its adverse effects extend beyond bone and mineral meta-
bolism. Numerous studies have demonstrated associations
with mortality, cardiovascular disease, insulin resistance,
diabetes, autoimmune disease, infection, and inflamma-
tion.1,2 Chronic kidney disease (CKD) imposes a heavy
burden of cardiovascular, metabolic, and infectious compli-
cations,3 and vitamin D deficiency is likely an important
modifiable risk factor in this high-risk population. Recent
studies in CKD linked vitamin D deficiency with extraskeletal
comorbidities, including insulin resistance,4,5 anemia,6,7 and
inflammation.8,9 In prospective studies of adults with CKD,
low serum 25-hydroxyvitamin D (25(OH)D) concentration
was an independent predictor of CKD progression and
mortality.10–12 Vitamin D deficiency may also contribute to
skeletal fragility in children with CKD.
Prior studies in children with CKD reported that the
prevalence of vitamin D deficiency (25(OH)D concentration
o20 ng/ml) ranged from 28 to 58%.13–18 Vitamin D defi-
ciency is also common in otherwise healthy children;B14 to
25% of children and adolescents have 25(OH)D concen-
trations o20 ng/ml.19–22 The risk factors for vitamin D
deficiency include African ancestry, older age, female sex,
geographic location, and winter season. CKD may impose
additional risk factors for vitamin D deficiency, includ-
ing impaired cutaneous photosynthesis of calciferol due to
uremia,23 urinary losses of vitamin D–binding protein (DBP)
and albumin, and decreased dairy intake due to phosphate
restriction. With the exception of our recent study in
pediatric kidney transplant recipients,18 none of the studies
of vitamin D status in children with CKD included a
concurrent healthy reference group; therefore, the inde-
pendent effect of CKD severity is not known. Furthermore,
the impact of the underlying cause of CKD has not been
addressed.
The objectives of this study were to determine whether
vitamin D deficiency is more common among children
with CKD compared with healthy children, and to identify
CKD-specific risk factors for vitamin D deficiency, inde-
pendent of CKD severity. The secondary objectives were to
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determine the effect of vitamin D status on serum concen-
trations of parathyroid hormone (PTH), 1,25 dihydroxy-
vitamin D (1,25(OH)2D), and inflammatory markers among
children with CKD, independent of CKD severity.
RESULTS
Participant characteristics
We evaluated 182 children and adolescents with CKD, in the
age group of 5 to 21 years, and 276 healthy children at the
Children’s Hospital of Philadelphia (CHOP) and Cincinnati
Children’s Hospital Medical Center (CCHMC). Table 1 gives
the characteristics of healthy children and CKD participants,
categorized according to CKD stage as follows:24 stages 2 and 3
(estimated glomerular filtration rate (eGFR) 30–89ml/min per
1.73m2; n¼ 74), CKD stages 4 and 5 (eGFR o30ml/min per
1.73m2; n¼ 54), and stage 5D (maintenance dialysis; n¼ 54).
CKD participants were of similar age to healthy participants
except for those with CKD stage 5D who were older. CKD
participants were more likely to be males than healthy children,
as expected in childhood CKD. There were slight differences
between groups in the season in which participants were
studied, with CKD participants more likely to be studied in
winter months (November–April) than healthy children.
Similar proportions of CKD participants and healthy children
were taking a multivitamin supplement containing vitamin D.
Only one participant in the dialysis group was taking a
medication known to affect vitamin D (phenytoin).
The underlying cause of renal disease was categorized as
CAKUT (congenital anomalies of the kidney and urinary
tract; n¼ 104), including aplastic/hypoplastic/dysplastic/
cystic kidneys and obstructive uropathy; systemic inflamma-
tory disease (systemic lupus erythematosis and Wegener’s
granulomatosis) and glomerulonephritis (n¼ 24); focal
segmental glomerulosclerosis (FSGS, n¼ 33); and others
(n¼ 21). Median age at diagnosis of CKD was 4.5 years
(range, birth to 19.1 years), and median interval from CKD
diagnosis to study visit was 7.3 years (range, 0.1 to 20.8
years). Of the CKD participants on maintenance dialysis,
35 were on hemodialysis and 19 were on peritoneal dialysis.
Laboratory measurements
Abnormalities in mineral metabolism were more pronounced
in participants with greater severity of CKD (Table 2);
intact parathyroid hormone (iPTH) and phosphorus were
Table 1 | Characteristics of healthy reference and chronic kidney disease participants
Healthy
Chronic kidney disease stage groups
reference 2–3 4–5 5, Dialysis P-valuea
n 276 74 54 54
Estimated GFR
(ml/min per 1.73m2) — 46 (30–78)b 18 (7–29) — —
Age (years) 13.4±4.5c 13.1±4.2 14.0±4.0 15.4±3.8 0.02
Sex: male 139 (50%)d 39 (53%) 38 (70%) 30 (56%) 0.06
African ancestry 59 (21%) 15 (20%) 14 (26%) 19 (35%) 0.15
Height Z-score 0.37±0.89 0.39±1.3 1.15±1.22 1.10±1.25 0.0001
BMI Z-score 0.28±0.99 0.26±1.12 0.33±1.26 0.10±1.4 0.70
Tanner stage 0.05
1 75 (27%) 22 (31%) 14 (26%) 6 (11%)
2–3 56 (20%) 21 (29%) 14 (26%) 18 (34%)
4–5 144 (52%) 29 (40%) 26 (48%) 29 (54%)
Season: Nov–Apr 121 (44%) 47 (63%) 24 (44%) 30 (56%) 0.01
Vitamin D supplement
Usage X400 IU/day 43 (16%) 16 (22%) 6 (11%) 9 (17%) 0.44
Underlying renal disease 0.0001
CAKUT — 50 (48%) 35 (34%) 19 (18%)
Systemic inflammatory and glomerulonephritis — 8 (33%) 4 (17%) 12 (50%)
FSGS — 3 (9%) 10 (18%) 20 (61%)
Others — 13 (62%) 5 (24%) 3 (14%)
Receiving calcitriol therapy — 17 (23%) 40 (74%) 46 (85%) 0.0001
Receiving glucocorticoids — 5 (7%) 2 (4%) 14 (26%) 0.0008
Study site 0.03
CCHMC 68 (25) 29 (39%) 20 (37%) 19 (35%)
CHOP 208 (75%) 45 (61%) 34 (63%) 35 (65%)
Abbreviations: BMI, body mass index; CAKUT, congenital anomalies of the kidney and urinary tract; CCHMC, Cincinnati Children’s Hospital Medical Center; CHOP, Children’s
Hospital of Philadelphia; FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate.
aAnalysis of variance (ANOVA) for continuous variables and w2 test for categorical variables.
bMedian; range in parentheses (all such values).
cMean±s.d. (all such values).
dNumber; percentage in parentheses (all such values).
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significantly higher and serum 25(OH)D, calcium, and
1,25(OH)2D concentrations were significantly lower with
greater CKD severity. Serum albumin concentrations were
lower, and the proportion of participants with low albumin
concentrations (o3.0 g/dl) was higher, with greater CKD
severity. Serum markers of inflammation, C-reactive protein
(CRP), and interleukin-6 (IL-6) concentrations were signi-
ficantly higher with greater disease severity.
Predictors of vitamin D status in CKD and healthy participants
Table 3 summarizes the final multivariable linear and logistic
regression models that include significant predictors of
25(OH)D concentrations in CKD and healthy children.
Mean 25(OH)D concentration adjusted for covariates was
lower, and the risk of vitamin D deficiency (o20 ng/ml) was
higher, in late-stage renal disease (that is, stages 4–5D) CKD;
there was no apparent difference in 25(OH)D concentrations
between early-stage CKD and healthy children. Enrollment at
CHOP, older age, African ancestry, and winter season were
statistically significant independent predictors of lower
25(OH)D concentrations, whereas sex, Tanner stage, vitamin
D supplement usage, and body mass index Z-score were not
associated with 25(OH)D concentrations after adjusting for
other covariates (P40.05). There was no interaction between
season and CKD stage in predicting 25(OH)D concentrations
or vitamin D deficiency even when restricting the sample to
those with late-stage renal disease. Similarly, there was no
interaction between CKD stage and African ancestry or study
site in predicting 25(OH)D concentrations (P40.05).
CKD-specific predictors of vitamin D status
Among CKD participants, underlying cause of CKD and low
serum albumin concentration were associated with lower
25(OH)D concentrations. Mean (±s.e.) 25(OH)D concen-
trations, adjusted for age, African ancestry, location, season,
and CKD stage, by underlying renal disease category, were
Table 2 | Serum concentrations of calcitropic hormones, minerals, and inflammatory markers among healthy reference and
chronic kidney disease participants
Healthy
Chronic kidney disease stage
reference 2–3 4–5 5, Dialysis P-valuea
25(OH)D (ng/ml) 25.2±10.5b 29.5±12.8 21.4±12.8 15.6±9.9 o0.0001
(n=276) (n=74) (n=54) (n=54)
Vitamin D deficient
(25(OH)D o20 ng/ml) 31% (86/276) 26% (19/74) 50% (27/54) 74% (40/54) o0.0005
iPTH (pg/ml) 26 (9–61)c 48 (2–521) 148 (8–1046) 251 (8–1416) o0.0001
[19–34]c [27–68] [74–404] [108–607]
(n=112) (n=74) (n=54) (n=54)
1,25(OH)2D (pg/ml)
No calcitriol therapy 39 (11–101) 38 (15–78) 21 (5–40) 14 (8–21) o0.0001
[33–46] [29–47] [17–36] [9–20]
(n=276) (n=57) (n=14) (n=8)
On calcitriol therapy — 34 (15–51) 33 (18–149) 19 (5–78) o0.0001
[29–41] [26–45] [13–24]
(n=17) (n=40) (n=45)
Calcium (mg/dl)d — 9.4±0.5 9.1±0.8 8.7±1.3 o0.0001
(n=74) (n=53) (n=54)
Corrected calcium (mg/dl)e — 9.5±0.4 9.3±0.5 9.1±1.1 0.04
(n=74) (n=52) (n=54)
Phosphorus (mg/dl)d — 4.4±0.9 5.4±1.4 5.8±1.9 o0.0001
(n=73) (n=53) (n=54)
Albumin (g/dl)d — 4.1 (1.7–4.8) 3.9 (1.4–4.8) 3.5 (1.4–5.1) 0.0001
[3.8–4.3] [3.4–4.2] [3.1–3.8]
o3mg/dl — 5 (7%)f 6 (12%) 8 (15%) 0.33
(n=74) (n=52) (n=54)
CRP (mg/dl)d — 0.3 (0.2–33.0) 0.6 (0.2–1.9) 0.6 (0.2–4.4) 0.02
[0.2–0.6] [0.3–0.6] [0.3–1.0]
(n=74) (n=52) (n=54)
IL-6 (pg/ml)d — 0.95 (0.30–9.93) 1.21 (0.30–14.88) 2.55 (0.46–60.55) o0.0001
[0.63–1.68] [0.76–2.19] [1.61–4.97]
(n=68) (n=46) (n=48)
Abbreviations: 1,25(OH)2D, 1,25 dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; CRP, C-reactive protein; IL-6, interleukin-6; iPTH, intact parathyroid hormone.
aAnalysis of variance (ANOVA) or Wilcoxon rank sum test among groups.
bMean±s.d. (all such values).
cMedian; range in parentheses; interquartile range in brackets (all such values).
dNot measured on healthy reference participants.
eCorrected for serum albumin concentrations=total calcium (mg/dl)+0.8 (4-serum albumin (g/dl))
fNumber; percentage in parentheses (all such values).
692 Kidney International (2012) 81, 690–697
or ig ina l a r t i c l e HJ Kalkwarf et al.: Vitamin D status in childhood kidney disease
as follows: CAKUT 24.8±1.1 ng/ml; systemic inflammatory
disease and glomerulonephritis 19.2±2.1 ng/ml; FSGS
14.6±1.8 ng/ml; and others 25.5±2.2 ng/ml (Po0.0001).
Adjusted mean 25(OH)D concentration among participants
with a low albumin (o3.0 g/dl) was 11.1±2.2 ng/ml com-
pared with 23.5±0.9 ng/ml among participants with albumin
X3.0 g/dl (Po0.0001). Group differences persisted when
both diagnostic category and low albumin were included
in the same model. It is noteworthy that 58% (11/19) of
children with albumin o3.0 g/dl had 25(OH)D concen-
trations o10 ng/ml, and 95% (18/19) had 25(OH)D
concentrations o20 ng/ml. Serum 25(OH)D concentrations
were positively associated (r¼ 0.50, Po0.0001) with albumin
concentrations. Among dialysis patients, there was no
difference in mean 25(OH)D concentrations between those
who had received a prior transplant and those who had not
(14.7 vs. 16.0 ng/ml, P¼ 0.60). Current use of glucocorticoids
was not associated with 25(OH)D concentrations (P¼ 0.78).
The dialysis participant taking phenytoin had a 25(OH)D
concentration of 38 ng/ml, which was notably higher than
that of the other dialysis participants.
Predictors of iPTH concentrations in CKD participants
Multiple regression analyses revealed that natural logarithm
(ln) iPTH concentrations were positively associated with
serum phosphorus concentrations and CKD stage and nega-
tively associated with corrected serum calcium and 25(OH)D
concentrations (Table 4). There was no interaction bet-
ween albumin or low albumin concentration (o3.0 g/dl) and
25(OHD) concentrations for predicting iPTH concen-
trations, whether or not calcitriol treatment was included
in the regression model (all P40.28). Similarly, there was no
interaction between CKD stage and 25(OH)D concentrations
for predicting iPTH concentrations, whether or not calcitriol
treatment was included in the regression model (P40.12).
Predictors of 1,25(OH)2D concentrations in CKD and healthy
participants
Among healthy children and CKD participants not receiving
calcitriol, there was a significant interaction between
25(OH)D concentration and CKD stage for predicting
1,25(OH)2D concentrations (Po0.0001), with the relation-
ship being greater in more advanced CKD. For a 1 ng/ml
increase in 25(OH)D concentration, 1,25(OH)2D concentra-
tions increased as follows: healthy children, 0.4% (n¼ 275,
Table 3 | Predictors of vitamin D concentrations and vitamin D deficiency in healthy reference and CKD participants: results
from multiple linear regression and logistic regression modeling
Deficient Severely deficient
25(OH)D (ng/ml) 25(OH)D o20ng/ml 25(OH)D o10 ng/ml
CKD stage Po0.0001 Po0.0001 P=0.0002
Healthy reference (n=276) 24.2±0.7a 1.00 1.00
2–3 (n=74) 26.6±1.1 1.12 (0.54–2.32) 1.56 (0.53–4.59)
4–5 (n=54) 20.9±1.3 2.77 (1.32–5.81) 4.24 (1.68–10.71)
5D (n=54) 16.1±1.3 10.28 (4.48–23.61) 6.38 (2.59–15.60)
Season Po0.0001 Po0.0001 P=0.0009
May–Oct (n=222) 24.9±0.7 1.00 1.00
Nov–Apr (n=236) 19.0±0.8 4.55 (2.64–7.86) 3.22 (1.56–6.64)
Age (years) Po0.0001 Po0.0001 P=0.02
5–8.9 (n=79) 25.9±1.2 1.00 1.00
9–11.9 (n=86) 22.8±1.1 1.29 (0.51–3.26) 3.27 (0.61–17.57)
12–14.9 (n=108) 20.1±1.0 5.21 (2.24–12.12) 4.62 (0.94–22.72)
15–21.9 (n=185) 19.0±0.8 6.59 (2.93–14.82) 7.18 (1.55–33.09)
African ancestry Po0.0001 Po0.0001 Po0.0001
No (n=350) 27.4±0.6 1.00 1.00
Yes (n=107) 16.4±1.0 16.66 (8.61–32.24) 8.78 (4.41–17.45)
Study site Po0.0001 P=0.007 P=0.03
CCHMC (n=136) 24.2±0.9a 1.00b 1.00
CHOP (n=321) 19.6±0.7 2.28 (1.26–4.15) 2.54 (1.06–6.08)
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CCHMC, Cincinnati Children’s Hospital Medical Center; CHOP, Children’s Hospital of Philadelphia; CKD, chronic kidney disease.
aLeast squares means±s.e. (all such values).
bOdds ratio; 95% confidence interval (95% CI) in parentheses (all such values).
Table 4 | Predictors of serum iPTH concentrations among CKD
participants
Estimatea P-value




Serum phosphorus (mg/dl) 25.8% o0.0001





Abbreviations: 5D, 5, dialysis; 25(OH)D, 25-hydroxyvitamin D; CKD, chronic kidney
disease; iPTH, intact parathyroid hormone.
aThe least squares mean (95% confidence interval) or the percentage change in iPTH
concentrations per unit change in predictor variable.
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P¼ 0.01); CKD stages 2 and 3, 0.7% (n¼ 57, P¼ 0.04); CKD
stages 4 and 5, 4.2% (n¼ 14, P¼ 0.006); CKD stage 5D, 2.3%
(n¼ 8, P¼ 0.15). When accounting for 25(OH)D concentra-
tion and CKD stage, ln iPTH concentration was positively
associated (b¼ 0.10, P¼ 0.02) with ln 1,25(OH)2D concen-
tration, which was consistent with iPTH effects to upregulate
the renal 1a-hydroxylase.
Association between vitamin D status and inflammation in
CKD participants
In bivariate analyses, ln CRP concentrations were inversely
associated with 25(OH)D concentrations (r¼0.31,
Po0.0001, excluding two extreme outliers), and CRP
concentrations were positively associated with greater CKD
severity (P¼ 0.02; Table 2). These relationships persisted
when including both in a multiple regression model
(25(OH)D concentration P¼ 0.009, CKD stage P¼ 0.01).
In bivariate analyses, ln IL-6 concentrations were inversely
associated with 25(OH)D concentrations (r¼0.22,
P¼ 0.008), and with CKD stage (Po0.0001; Table 2). When
both were fitted in a multiple regression model, 25(OH)D
concentrations were no longer associated with IL-6 concen-
trations (P¼ 0.88), whereas CKD stage remained significant
(Po0.001); geometric means (95% confidence interval) were
as follows: CKD stages 2 and 3, 1.09 (0.87–1.36), stages 4 and
5, 1.31 (1.02–1.69), and stage 5D, 2.79 (2.14–3.63). Serum
1,25(OH)2D concentrations were not associated with IL-6
or CRP, adjusted for CKD severity.
DISCUSSION
This is the first study to compare the vitamin D status of a
large sample of children and adolescents with CKD stages
2–5D with healthy children. Inclusion of healthy children is
an important strength given the high background preva-
lence of vitamin D deficiency in the general pediatric US
population.19,20 Analyses confirmed that 25(OH)D deficiency
was common among healthy children (31%;o20 ng/ml) and
demonstrated that late-stage CKD was associated with
significantly greater odds of 25(OH)D deficiency, compared
with healthy children, even when adjusted for age, African
ancestry, location, and season. Furthermore, these analyses
demonstrated that the association of season with 25(OH)D
deficiency did not vary according to CKD stage, suggesting
that impaired dermal photosynthesis of vitamin D did not
contribute substantially to the lower 25(OH)D concentra-
tions in advanced CKD.
This study advances our understanding of the indepen-
dent effects of hypoalbuminemia and the underlying cause
of renal disease on vitamin D status. Serum 25(OH)D concen-
trations among participants with a low serum albumin
(o3.0 g/dl) were profoundly lower than concentrations in
participants with albumin X3.0 g/dl: 11.1 vs. 23.5 ng/ml,
independent of CKD severity and underlying renal disease.
Prior studies in CKD reported that 25(OH)D concentrations
were positively associated with serum albumin25,26 and
inversely associated with the degree of proteinuria16,27,28 and
albuminuria.8 Patients with significant proteinuria represent
a unique population with respect to vitamin D status owing
to the urinary losses of DBP and albumin, to which 499%
of circulating 25(OH)D and 1,25(OH)2D are bound.29 Total
serum 25(OH)D concentrations may not reflect bioavailable
or free vitamin D when serum DBP and albumin are reduced,
and the clinical significance of low 25(OH)D concentrations
in these individuals is not known. However, we did not detect
an interaction between 25(OH)D and serum albumin for
predicting iPTH concentrations; CKD participants with low
25(OH)D and hypoalbuminemia had comparable compensa-
tory increases in iPTH concentrations, suggesting a 25(OH)D
deficiency state.
The underlying cause of renal disease, especially FSGS, was
a significant risk factor for vitamin D deficiency, independent
of hypoalbuminemia and CKD severity. FSGS is often
associated with significant or nephrotic-range proteinuria.
Although serum albumin is affected by the magnitude of
proteinuria, it does not necessarily reflect the duration or
selectivity of proteinuria. Therefore, the comparatively worse
vitamin D status of subjects with FSGS could be partly
attributable to protracted urinary losses of albumin and DBP.
In addition, subjects with FSGS may have a disproportionate
burden of proximal tubular dysfunction or injury. In the
kidney, vitamin D–DBP complexes are freely filtered by the
glomerulus and reabsorbed via megalin/cubilin-mediated
endocytosis in the proximal tubule.30,31
We found an association between 25(OH)D deficiency
and higher iPTH concentrations in children and adolescents
with CKD, independent of serum phosphorus and calcium
concentrations and CKD severity. There was no evidence of a
CKD–25(OH)D interaction, indicating that 25(OH)D defi-
ciency is associated with a comparable increase in iPTH
across all CKD stages. As eGFR declines, 1-a-hydroxylation of
25(OH)D to 1,25(OH)2D is impaired, leading to a compen-
satory rise in iPTH. Prior studies of 25(OH)D and iPTH
concentrations in children with CKD demonstrated conflict-
ing results and did not adjust for the confounding effects of
CKD severity.16,17 We recently demonstrated that higher
25(OH)D at the time of transplantation and greater increases
in 25(OH)D following transplantation were independently
associated with greater decreases in iPTH in pediatric renal
transplant recipients.18
Prior studies in adults with CKD have documented a
positive association between 25(OH)D and 1,25(OH)2D
concentrations.25,27,32,33 However, this is the first study to
demonstrate that this association differed significantly accord-
ing to CKD severity; the slope between 25(OH)D and
1,25(OH)2D was steeper as CKD severity progressed. This
suggests a greater substrate dependence in more advanced
CKD, and that 25(OH)D adequacy is important in CKD for
renal production of circulating 1,25(OH)2D in advanced
CKD when 1a-hydroxylase activity is most compromised.
Recent studies in patients with CKD have demonstrated
an inhibitory effect of vitamin D on renal and systemic
inflammation. Zehnder et al.34 demonstrated an inverse
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association between urinary concentrations of the chemo-
kine, macrophage chemoattractant protein-1, and serum
25(OH)D and 1,25(OH)2D concentrations in CKD patients.
The 1,25(OH)2D concentrations were also inversely corre-
lated with renal macrophage infiltration. Stubbs et al.9
treated 25(OH)D-deficient end-stage renal disease patients
with cholecalciferol and demonstrated decreased circulating
tumor necrosis factor-a, IL-6, and IL-8 concentrations. To
our knowledge, our study is the first to report an association
between CRP and 25(OH)D in children and adolescents with
CKD that persisted when adjusting for CKD stage.
This study has some limitations. We do not have infor-
mation on sun exposure. It is possible that children and
adolescents with CKD spend less time outdoors and that
their vitamin D deficiency is attributable, in part, to sun
exposure. However, the association of season with 25(OH)D
status was comparable in CKD and healthy participants,
suggesting that difference in sun exposure did not confound
the analyses adjusted for season. We do not have information
on dietary vitamin D intake, although we accounted for
vitamin D supplement usage. Phosphate restriction in
advanced CKD may have contributed to lower 25(OH)D
concentrations via reduced dairy intake. We do not have data
on urine protein excretion or protein intake. Serum albumin
is influenced by nutritional status, as well as proteinuria;
therefore, some of the associations between 25(OH)D and
albumin concentrations may relate to nutritional status
rather than proteinuria. However, in our recent study in this
cohort, lean mass deficits were not associated with lower
serum albumin concentrations.35 The use of non-fasting
blood samples may have increased the variability in serum
calcium and phosphorus concentrations, and thereby iPTH
concentrations, making it more difficult to detect subtle
effects. Last, the cross-sectional design limits our ability to
make causal inferences.
Accurate and reliable measurement of 25(OH)D concen-
trations is necessary for valid comparisons between groups
and when assessing the impact of potential risk factors and
prevalence estimates. Accuracy and reliability of 25(OH)D
measurements has been an issue owing to differences in assay
methods and the need for consistent skilled laboratory
techniques and reagents, respectfully.36 All of our samples
were measured using the DiaSorin assay in a single highly
experienced laboratory that achieved International Vitamin
D External Quality Assessment Scheme (DEQAS) certifica-
tion;37 DEQAS aims to ensure the analytical reliability of
25(OH)D and 1,25(OH)2D assays through quarterly testing
of pooled specimens.38 The DiaSorin radioimmunoassay
assay, when performed in a highly proficient laboratory, has
been shown to be similar to the high-performance liquid
chromatography reference method36 and the NIST (National
Institute of Standards and Technology) liquid chromato-
graphy/mass spectrometry assay.39 Our consistent laboratory
methodology minimizes the likelihood of measurement bias
affecting comparisons between groups. However, residual
measurement error increases the variability in 25(OH)D
concentrations, thereby reducing the statistical power to
detect underlying relationships. This would have resulted in
failure to detect associations. In addition, assay bias, even if
small, would result in over- or underestimation of prevalence
estimates of vitamin D deficiency.
In summary, we showed that vitamin D deficiency was
more common in children and adolescents with late-stage
CKD. Vitamin D status was worse in the presence of hypo-
albuminemia and among those with FSGS. Lower 25(OH)D
concentrations were associated with lower circulating
1,25(OH)2D concentrations, especially in late-stage CKD.
Lower 25(OH)D concentration was also associated with
higher iPTH and CRP concentrations, independent of CKD
severity. Thus, vitamin D deficiency is a highly prevalent and
modifiable risk factor in children and adolescents with CKD,
contributing to the disordered mineral metabolism and
inflammation in this high-risk population. Trials of vitamin
D supplementation are needed to determine the effect of
repletion on clinical outcomes.
MATERIALS AND METHODS
Study participants
This cross-sectional study was conducted as part of a larger study of bone
health in children and adolescents with CKD, in the age group of 5 to 21
years, at CHOP and CCHMC. A total of 182 individuals with CKD
stages 2–5 were included in this study sample (CHOP, n¼ 114; CCHMC,
n¼ 68). Recruitment and data collection were carried out between
January 2002 and November 2006. Subjects with cognitive or develop-
mental disorders preventing completion of the study procedures were
ineligible. Prior transplantation was an exclusion criterion in children
with predialysis CKD, but not in dialysis patients. We recently reported
that greater CKD severity was associated with greater muscle deficits in
these participants.35 Changes in serum vitamin D concentrations
following renal transplantation were reported in a sample of 58 children
and adolescents;18 however, disease-specific risk factors for vitamin D
deficiency were not assessed, and the limitation of the study to end-stage
renal disease precluded analyses of the impact of CKD severity.
Healthy children (n¼ 276), in the age group of 5 to 21 years,
were recruited from general pediatrics practices or community
advertisements in the greater Philadelphia (n¼ 208) and Cincinnati
(n¼ 68) areas. Healthy participants were ineligible if they had
chronic illnesses or were on medications potentially affecting
growth, maturation, or nutritional status.
The Institutional Review Boards at CHOP and CCHMC
approved the study protocol. Informed consent from study subjects
X18 years of age, as well as assent along with parental consent from
subjects o18 years of age were obtained.
Anthropometry, sexual maturity, and African ancestry
Height was measured with a stadiometer and weight with a digital
scale. Measurements were obtained in triplicate. Height and body
mass index (kg/m2) Z-scores were calculated using the CDC (Centers
for Disease Control) 2000 growth reference.40 Sexual maturity was
determined by self-assessment41 and classified according to Tanner
stage criteria.42 Information on ancestry was obtained by self-report.
Laboratory measurements
Non-fasting blood samples were collected in the CKD and healthy
participants. Serum 25(OH)D and 1,25(OH)2D concentrations were
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measured by radioimmunoassay with I125-labeled tracer (DiaSorin,
Stillwater, MN) in the laboratory of Dr Bruce Hollis.43 Intraassay
coefficient of variation (CV) was 2.2% for 25(OH)D and 7–11%
for 1,25(OH)2D.
44 The laboratory of Dr Hollis has been involved
in DEQAS since 1997 and has received certification with regard
to the analytical reliability of 25(OH)D and 1,25(OH)2D assays
performed every year.37 The iPTH concentrations were measured
by radioimmunoassay with 125I-labeled antibody with a CV of
3–5% (Scantibodies Clinical Laboratory, Santee, CA). Laboratory
measurements on healthy participants were recorded in the same
laboratories concurrently with those from CKD participants and
included 25(OH)D and 1,25(OH)2D (n¼ 276) and iPTH (n¼ 119).
The following were obtained in CKD participants only: CRP (low
sensitivity) was measured using a fixed-point immuno-rate method
(Vitros, Johnson & Johnson, Rochester, NY) with a CV of 3–8%.
IL-6 was measured by high-sensitivity solid-phase enzyme-linked
immunosorbent assay (R&D Systems, Minneapolis, MN) with a CV
of 8%. Serum albumin was measured by spectrophotometric
enzymatic assay (Vitros, Johnson & Johnson) with a CV of 1–2%.
Serum calcium and phosphorus were measured in the clinical
laboratories using standard methods with CVs of 1.3% andp2.1%,
respectively; calcium concentration was adjusted for albumin
concentration.45 Serum creatinine concentration was measured by
a spectrophotometric enzymatic assay (Vitros, Johnson & Johnson)
with a CV of 1–5%. The eGFR (ml/min per 1.73m2) was calculated
based on height and serum creatinine using the pediatric estimating
equation generated in the Chronic Kidney Disease in Children
(CKiD) Prospective Cohort Study.46 CKD participants were catego-
rized into three groups according to CKD stage as defined by
the National Kidney Foundation KDOQI (Kidney Disease
Outcomes Quality Initiative) guidelines:24 CKD stages 2 and 3
(eGFR 30–89ml/min per 1.73m2; n¼ 74), CKD stages 4 and 5
(eGFR o30ml/min per 1.73m2; n¼ 54), and stage 5D (main-
tenance dialysis; n¼ 54).
Disease characteristics and medications
Medical charts were reviewed for the date of diagnosis of CKD,
underlying etiology of renal disease, dialysis history, and current and
past active vitamin D sterol treatment. Current medication use and
information on vitamin D intake from multivitamins and dietary
supplements was obtained by means of a questionnaire. Among
those taking a vitamin D–containing supplement, the median
intake was 400 IU/day (range 14–650). For subsequent analyses,
vitamin D supplement use was dichotomized asX400 IU/day versus
o400 IU/day.
Statistical analyses
Statistical analyses were performed with the JMP statistical
software, version 8.0 (SAS Institute, Cary, NC). The frequency
distributions of all variables were assessed for normality. Non-
normally distributed variables (iPTH, 1,25(OH)2D, CRP, and IL-6
concentrations) were log-transformed to better approximate
normality. Serum 25(OH)D concentrations were categorized as
deficient (o20 ng/ml), in accordance with the 2011 Report on
Dietary Reference Intakes for calcium and vitamin D from the
Institute of Medicine,47,48 or severely deficient (o10 ng/ml).
Season was categorized as summer (May–October) versus winter
(November–April); summer months had the highest mean 25(OH)D
concentrations among white healthy participants. Descriptive
characteristics of the study groups were compared by analysis of
variance, Kruskal–Wallis, or w2 tests.
Multivariable linear and logistic regression analyses were
performed to compare mean 25(OH)D concentrations and risk of
vitamin D deficiency between healthy and CKD groups adjusting for
age, sex, African ancestry, body mass index Z-score, Tanner stage,
use of vitamin D supplements, season, and study site. Variables were
kept in the regression models if P-value was o0.05. Multiplicative
interactions between CKD stage and season, African ancestry, and
study site were tested. Separate multiple linear regressions models
were conducted within CKD participants to assess CKD-specific
predictors of 25(OH)D concentration. CKD-specific factors were
underlying renal diagnosis, CKD severity, and low serum albumin
concentration (o3.0 g/dl).
Multivariable regression analyses were conducted to determine the
effect of 25(OH)D concentration on iPTH, 1,25(OH)2D, CRP, and
IL-6 concentrations among CKD participants. Because these variables
were log-transformed for analyses, we presented results for categorical
predictor variables as geometric means and 95% confidence interval,
and for continuous predictor variables as the percentage change in
Y associated with a unit change in X. Serum iPTH concentration was
modeled as a function of the following independent variables: serum
phosphorus, corrected calcium, calcitriol use, and 25(OH)D
concentration; interactions between serum 25(OH)D concentration
and CKD stage, and between 25(OH)D and albumin concentrations,
were tested. Serum 1,25(OH)2D was modeled as a function of
25(OH)D, CKD stage, and the interaction between CKD stage and
25(OH)D concentration. CKD participants who were receiving
calcitriol therapy were excluded from these analyses. Both CRP
and IL-6 concentrations were modeled as a function of 25(OH)D
concentration and CKD stage.
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